PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tranexamic acid - Fibrinolysis
PAD Profile : Tranexamic acid - Fibrinolysis Important
Keywords :
menorrhagia, heavy mentrual bleeding, hereditary angioedema, epistaxis, nose bleeds
Brand Names Include :
Cyklokapron
Important Information :
Includes menorrhagia, epistaxis and local fibrinolysis
Traffic Light Status
Status 1 of 3.
Status :
Green
Formulations :
- Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 3.
Status :
Red
Formulations :
- Injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 3 of 3.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Tranexamic acid has been considered by the PCN and has been assigned a GREEN traffic light status, within its LICENSED indication(s).
NOTE - the branded product (Cyklokapron) was considered BLACK at the PCN in May 2017.
Associated BNF Codes
02. Cardiovascular System
02.11.00. Antifibrinolytic drugs and haemostatics